Sandoz Shields Generic Drugs in Medicaid Rebate Program Suit

Sandoz Inc. is challenging the Centers for Medicare & Medicaid Services over any agency actions that would classify two of its products as innovator drugs under a government rebate program.

The Wednesday complaint in the US District Court for the District of Columbia comes six years after the agency in April 2018 advised Sandoz that its two drugs, Anectine and brimonidine tartrate, should be classified as innovator drugs under the statute that established the Medicaid Drug Rebate Program.

Innovator drugs are newly developed and are first of their kind, while a non-innovator drug is a generic drug, also known as ...